{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "b963d586a29ede85aa4cf295175db9b6",
    "title": "Jefferies",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/Jefferies/All Hopes On Better H2 TrendsAll Hopes On Better H2 Trends_2025-08-28",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T12:16:49.062734",
      "extracted_at": "2025-10-26T12:16:49.062756"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 16,
        "successful_pages": 16,
        "date": "2025-08-28",
        "publication": "25.9月 普通个人版/9.1 普通个人版/Jefferies",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 2,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.09389719354255299
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/Jefferies"
      }
    }
  },
  "passages": [
    {
      "passage_id": "f24f85a8e4f73cab",
      "text": "EUROPE I Medical Supplies & Devices",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d851e3484d49f425",
      "text": "Slow start to the year as guided with Q1 results broadly in line: OSG 2.5% (cons \\(+1.9\\%),\\) adj mgin 6.5% (cons 6.1%) and order book down 1%cc (cons-2%).Vague FY25/26 guide (sales growth; no mgin target) reiterated, as is MT guide for mgin returning to 14% and higher. Shares down \\(\\sim 25\\%\\) YTD, reflecting external pressures (tariffs, hospital budget, FX HWs), a mixed track-record on execution (share losses, Evo's US approval delayed) and a new CEO.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "dd5caa754b1d5a07",
      "text": "**Orders still in negative territory.** Facing tough comps \\((+10\\%\\) in 1Q24/25), the order book declined 1%cc (cons -2%cc). This is in spite of the recent launch of new Iinac Evo and new additions to the software suite Eleta ONE. B2B stands at 1.05x (1.09x on a rolling 12M). We continue to question EKTAB's ability to sustain top-line momentum in light of uninspiring order intake (avg down \\(>1\\%\\) over the past 2Y).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "08182e65ef1e4741",
      "text": "**Sales in line.** Q1 OSG reached 2.5% (cons \\(+1.9\\%),\\) mainly driven by strong performance in Europe while China and US sales continued to decline. As is usually the case, Q1 sales were skewed towards Service \\((+4\\%cc)\\) vs Solutions \\((+1\\%)\\) .",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a0462d98ea99c9c2",
      "text": "**Savings initiatives partly mitigate FX/tariff pressure.** As previously flagged, EKTAB has taken actions to improve profitability (price hikes and cost savings). This helped to limit the adj GM pullback (down 80bp y/y), burdened by FX (100bp) and tariffs (90bp). Adj. EBIT margin landed at 6.5% (cons 6.1%), down 90bp y/y. We stress Q1 usually accounts for \\(\\sim 10\\%\\) of FY EBIT due to seasonality.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "46c222a1740fe07d",
      "text": "**Vague FY25/26 guide reiterated.** EKTAB expects sales to grow in FY25/26 (cons. \\(+4.6\\%cc)\\) but still no mgin target (cons. 11.7% vs 11.6% in FY24/25). Q2 sales are expected to be negatively impacted by continued US weakness and uninspiring order intake from China last year (China sales recovery expected in 2H25/26), with mgmt implicitely guiding to lack of organic growth. Besides, EKTAB foresees a continuous negative impact on earnings from FX/tariffs in Q2.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "eba11b96d9736a98",
      "text": "**A stronger H2 backed by better US/China trends.** EKTAB is aiming for sales/margin to step up in H2, driven by the recovery in US (Evo approval hopefully in the coming weeks/months) and in China (order pickup).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d0900b1b63a50ab3",
      "text": "**Ambitious MT guide still valid.** EKTAB aims for higher Gross/EBIT mgin, driven by price hikes, innovation and volumes resulting in a stepwise improvement towards the long-standing MT targets to move GM back to pre-COVID levels ( \\(>40\\%\\) ) and EBIT mgin \\(>14\\%\\) (cons 12.9% in FY28/29). More precise financial targets/pathway will likely be at the initiative of the incoming CEO Jakob Just-Bomholt.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4f87f05e059d69d1",
      "text": "**Among the sector's weakest performers.** EKTAB shares have shed \\(\\sim 30\\%\\) in the past yr, and now trade Real all-time lows of \\(\\sim 13x\\) P/E CY26e. This reflects rising operational challenges (US, China), tariff uncertainties, a weak start to FY25/26 and CEO change. The prospect of faster earnings momentum from next FY is unlikely to hearten investors in our view, given the co's mixed record on execution.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2ebcb5681d253d95",
      "text": "Rev. (MM)18,119.418,015.917,405.518,120.2B2B (missed Chat Series: Register2,161.1Adj EPS3.623.083.253.72Cons. Rev.18,119.418,015.917,765.618,632.2",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "beadce7523d1598f",
      "text": "Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 11-16 of this report.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4ffe7b6c2d49a488",
      "text": "* Jefferies GmbH * Jefferies International Limited",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f050c430240b1253",
      "text": "COMPANY UPDATERATINGHOLDPRICESEK48.94*PRICE TARGET|% TOPSEK53.00|+8%52W HIGH-LOWSEK76.30-SE K40.64FLOAT (%)|ADV MM (USD)94.5%|3.63MARKET CAPSEK18.78|$2.0BTICKEREKTAB SS",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "62c3b166963fa39d",
      "text": "*Prior trading day's closing price unless otherwise noted.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "08264a04239e6d81",
      "text": "FY (Apr)CHANGE TO JEFeJEF vs CONS",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ee78b5a70c341a1f",
      "text": "REV*NM&lt;1%-2%-3%EPS*+1%&lt;-1%-7%-7%",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4d5b9b666ea592e1",
      "text": "2026 (SEK)Q1Q2Q3Q4FYEPS*----+3.25",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "2395c9e4bb5ad567",
      "text": "All Hopes On Better H2H2H2H2H2H2H2H2H2H2H2",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "49310e5d604a911b",
      "text": "**Orders still in negative territory.** Facing tough comps \\((+10\\%\\) in 1Q24/25), the order book declined 1%cc (cons -2%cc). This is in spite of the recent launch of new Iinac Evo and new additions to the software suite Eleta ONE. B2B stands at 1.05x (1.09x on a rolling 12M). We continue to question EKTAB's ability to sustain top-line momentum in light of uninspiring order intake (avg down \\(>1\\%\\) over the past 2Y).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "51a59e242dc42854",
      "text": "**Sales in line.** Q1 OSG reached 2.5% (cons \\(+1.9\\%),\\) mainly driven by strong performance in Europe while China and US sales continued to decline. As is usually the case, Q1 sales were skewed towards Service \\((+4\\%cc)\\) vs Solutions \\((+1\\%)\\) .",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "84ec1c0bc8e3bf86",
      "text": "**Savings initiatives partly mitigate FX/tariff pressure.** As previously flagged, EKTAB has taken actions to improve profitability (price hikes and cost savings). This helped to limit the adj GM pullback (down 80bp y/y), burdened by FX (100bp) and tariffs (90bp). Adj. EBIT margin landed at 6.5% (cons 6.1%), down 90bp y/y. We stress Q1 usually accounts for \\(\\sim 10\\%\\) of FY EBIT due to seasonality.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a3765710d0ebfb18",
      "text": "**Vague FY25/26 guide reiterated.** EKTAB expects sales to grow in FY25/26 (cons. \\(+4.6\\%cc)\\) but still no mgin target (cons. 11.7% vs 11.6% in FY24/25). Q2 sales are expected to be negatively impacted by continued US weakness and uninspiring order intake from China last year (China sales recovery expected in 2H25/26), with mgmt implicitely guiding to lack of organic growth. Besides, EKTAB foresees a continuous negative impact on earnings from FX/tariffs in Q2.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b8b22b263fb1bb0e",
      "text": "**A stronger H2 backed by better US/China trends.** EKTAB is aiming for sales/margin to step up in H2, driven by the recovery in US (Evo approval hopefully in the coming weeks/months) and in China (order pickup).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "a98ad987f7d2a1ac",
      "text": "**Ambitious MT guide still valid.** EKTAB aims for higher Gross/EBIT mgin, driven by price hikes, innovation and volumes resulting in a stepwise improvement towards the long-standing MT targets to move GM back to pre-COVID levels ( \\(>40\\%\\) ) and EBIT mgin \\(>14\\%\\) (cons 12.9% in FY28/29). More precise financial targets/pathway will likely be at the initiative of the incoming CEO Jakob Just-Bomholt.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ae67b1cbcca76e58",
      "text": "**Among the sector's weakest performers.** EKTAB shares have shed \\(\\sim 30\\%\\) in the past yr, and now trade Real all-time lows of \\(\\sim 13x\\) P/E CY26e. This reflects rising operational challenges (US, China), tariff uncertainties, a weak start to FY25/26 and CEO change. The prospect of faster earnings momentum from next FY is unlikely to hearten investors in our view, given the co's mixed record on execution.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "551b584bd8ba0c50",
      "text": "**Rev. (MM)** 18,119.4 18,015.9 17,405.5 18,120.2",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1b7a73ba20e543ed",
      "text": "**B2B (missed Chat Series: Register** **HERE for any of the confirmed >40 companies.** 2,161.1",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b6a8eb169c405fc0",
      "text": "**Adj EPS** 3.62 3.08 3.25 3.72",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "fdbf00350b9b0726",
      "text": "**Cons. Rev.** 18,119.4 18,015.9 17,765.6 18,632.2",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "b7c90928aaaec109",
      "text": "- Order growth lagging sales target for over 2 years; thus, MT guidance relies mainly on backlog conversion (uncertain quality given it has risen significantly in past decade).- EKTAB's mkt share has not benefited from its focus on Unity since 2018 - lack of commercial traction, clear barriers to adoption and peer ViewRay's Chapter 11.- SHL/VAR combination signals fiercer competition given large customer base in Imaging, its legacy installed base in the RT market, and the breadth of the combined solutions portfolio.- Margin should recover from supply challenges and input cost inflation, despite necessary R&D efforts.- Challenges seem fairly reflected in the shares trading close to an all-time low valuation.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f6c6d3e3fa19cf3d",
      "text": "Risk/Reward - 12 Month View",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "29a6381cb4509d36",
      "text": "- Oligopolistic market with high barriers to entry, increased competition following VAR/SHL merger.- 2025/26 to 2029/30e sales CAGR of \\(4 - 5\\%\\) - Adj EBIT margin \\(>13\\%\\) by 29/30e.- Implied CY25e P/E multiple of \\(\\sim 17x\\)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "7d3bc7715c948e9f",
      "text": "- Order book surprises on the upside and \\(4 - 5\\%\\) OSG in FY25/26e.- Margin recovers to \\(12 - 13\\%\\) in \\(25 / 26e\\) .- \\(30\\%\\) discount to EU MedTech.- Implied CY25E P/E multiple of \\(\\sim 19x\\)",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "ad883d8f5cb9a6ba",
      "text": "- Order book surprises on the downside and installation challenges limit OSG to \\(0\\%\\) in FY25/26e.- Margin declines y/y to \\(\\sim 10\\%\\) in \\(25 / 26e\\) - Discount to EU MedTech expands to \\(50\\%\\) .- Implied CY25E P/E multiple of \\(\\sim 13.5x\\) .",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "465a26db1d549261",
      "text": "Top Material Issue(s): (1) Maintaining product quality & safety requiring ongoing robust compliance procedures and internal controls. (2) Patient access to medical technologies in both low- income and middle- income countries and the developed world and access to educated healthcare professionals. (3) Establish responsible and resilient supply chains.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "16e45506ac0c8785",
      "text": "ESG targets: (1) Increase the installed base by 825 linacs in underserved market by April 30, 2025, compared to April 30, 2020. (2) Increase eNPS (employer net promoter score) to 34 by 2024/25. (3) Reduce voluntary attrition rate to \\(7\\%\\) by 2023/24.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "76856cb32f094929",
      "text": "Questions to management: (1) How does your company plan to identify and improve its internal quality control systems to maintain product quality & safety? (2) What can be done to improve access to cancer care and what enhancements can be made to shorten the time from order to install? (3) What differentiates the company as an employer of choice within the healthcare sector?",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4c0531c1d9d848fd",
      "text": "ESG Sector Integration: Medical Equipment & Supplies",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c105bb7755b102f6",
      "text": "Elekta results vs consensus",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2af84624f45b991e",
      "text": "Exhibit 1 - Elekta results vs consensusApr year-end (SEK m)1Q24/25actual1Q25/26actual1Q25/26econs.actual vs cons.FY24/25actualFY25-26 guide at FY24/25FY25-26 guide at 1Q25/26FY25/26econs.JFEe vscons.Total Orders4,1923,8383,8220%19,71919,32119,3390%% reported growth9%(8%)(9%)0%(2%)(2%)% growth at CER10%(1%)(2%)2%4%4%Sales - Americas1,2411,0711,0235%5,1834,8024,8080%% organic16%(4%)(7%)(2%)3%2%Sales - EMEA1,3141,4431,3814%6,5806,6946,7050%% organic(12%)15%8%1%5%4%Sales - APAC1,2701,1321,232(8%)6,2546,1285,893(4%)% organic3%(4%)5%4%6%1%Group sales3,8253,6463,6360%18,01617,62317,405(1%)% reported growth(0.1%)(4.7%)(4.9%)(0.6%)(2.2%)(3.4%)% organic0.8%2.5%1.9%1.0%sales growthsales growth4.6%2.5%% FX(0.8%)(7.2%)(6.9%)(1.3%)(6.8%)(5.9%)Adj EBIT2832352217%2,0972,0691,975(5%)% of sales7.4%6.5%6.1%11.6%11.7%11.3%Adj EPS diluted0.410.310.2813%3.083.503.25(7%)% growth yoy(38%)(24%)(32%)(15%)14%6%",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "29c899e1f0914b02",
      "text": "Source: Infront, VA consensus, Company data, Jefferies estimates",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "49dd4651dbd6dde8",
      "text": "VA consensus used for OSG",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "92d998a6452a2f96",
      "text": "· EMEA +15% with performance supported by new product launches and France, UK and Poland starring",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4ac49b6f19546731",
      "text": "· APAC -4% with China weakness (anti-corruption has weighed and order book has become quite small, expect China sales to remain in negative territory in Q2 but expect pick-up and positive growth from H2) and India temporarily weak (usual lumpiness on a quarterly basis, but great MT potential given under-penetration)",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b4debeee1957d5aa",
      "text": "· Americas -4% with US weakness mainly related to customers awaiting Evo approval and \"a little bit of wait and see attitude\" among customers due to tariffs",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "471f6e7098c266ad",
      "text": "Unity - capability to treat prostate cancer while preserving erectile function gained significant attention",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "9f77376b1f2630a9",
      "text": "Leksell Gamma Knife received FDA clearance for treating a certain type of epilepsy - an important step towards expanding the scope of stereotactic radiosurgery",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "a9747015ecfcd7a5",
      "text": "Evo - will be positioned as a premium product - approval re-submitted but can not commit to any timeline (\"hopefully earlier than H2\")",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "055c307e15e505ab",
      "text": "Sales weakness to persist in US/China",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "0554109b683019c3",
      "text": "Despite easy comps, would not expect organic growth in Q2 but no formal guide",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2b54eb65df6e224f",
      "text": "No mgin guide but key to drive profitable growth",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "833668cbe68e3e90",
      "text": "Would not commit to \"a chance of growing margin in FY25/26\"",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b3ef19488cf8a098",
      "text": "At current rates, FX headwinds to come down gradually over FY25/26 from 100bp in Q1 up to a wash in Q4",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "cb360c7a5eced0b6",
      "text": "Committed to return to \\(14\\% +\\) EBIT margin helped by new products and savings initiatives",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "165fa96cea945acc",
      "text": "Aim for positive order growth over FY25/26",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9a40d4b0c4f46aa0",
      "text": "Lead time - 12M for typical linac, 12- 18M for GammaKnife, 18- 24M for Unity.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "08eff44bfee36d37",
      "text": "Exhibit 2 - Order intake still subdued",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "704a19e3ab2f766b",
      "text": "Source: Company data, JEF",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6a934d1ff88b190a",
      "text": "Exhibit 3 - Order slowdown is a concern for sales growth",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f95c7d1501fc07f8",
      "text": "Source: Company data, JEF",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cea97b1d0d3b2463",
      "text": "SEK33m impact or 90bp impact on GM in Q1 - expect similar continued negative impact throughout FY, even if pricing and supply chain changes should help going fd",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3eb7f58df66c726d",
      "text": "Have implemented a specific tariff clause in contracts and continue to adjust prices",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "fff9a2cdc9a66b5c",
      "text": "US sales are \\(21\\%\\) of Group sales incl 1/3 devices, 1/3 software and 1/3 service - software locally developed in the US and service by nature domestic (even if minor spare parts import) - hardware relies upon the UK, Netherlands and Sweden.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "e439ab77a2707d72",
      "text": "China - mostly local- for- local.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7319743e07173336",
      "text": "Have active mitigation measures in place to best handle the impact.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "d867198d0a9bc0c1",
      "text": "Expect further reduction in gross R&D (lower as \\(\\%\\) of sales y/y)",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7ff46f2b4158bb86",
      "text": "Capitalized R&D - expect amortization to remain elevated (>SEK800m in FY25/26e vs SEK841m in FY24/25) due to recent product launches; capitalization rate should continue to come down, leading to net capitalized R&D shrinking (5.2% of sales in FY22/23 to 3.0% in FY24/25 - JEF expect",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cef5c72d38dc676d",
      "text": "Exhibit 4-Change in Elekta estimates",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "132cff91bad23e02",
      "text": "Exhibit 6 - Elekta vs Medical Equipment P/E",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "fec10daddf7adb59",
      "text": "Exhibit 7 - Elekta vs EU MedTech P/E",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0be8edfc59ee37f5",
      "text": "Source:Factset,Jefferies",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "df6aeb5288f49ddf",
      "text": "Exhibit 9-EKTAB Balance Sheet",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "08336ca6b0ae53c4",
      "text": "Balance Sheet (SEKm)2013/142014/152015/162016/172017/182018/192019/202020/212021/222022/232023/242024/252025/262026/27eAssetsIntangible assets6,8458,1748,2108,7049,1759,3019,4698,77910,26211,72213,33611,91712,26612,605Tangible fixed assets6248818037958959579688979549801,0629011,0591,241Right-of-Use00000001156952.9975773116410061006Shares in associated companies50022424242421242634000Deferred tax assets143224281375350401504436616703801841841841Other financial fixed assets3543713652852194667064914911,0291,058895895895Fixed assets7,9719,6509,65910,18110,68111,16712,84511,59713,42315,23317,45515,56016,06716,589Inventories1,0781,2971,1359362,5602,6342,7482,2832,5333,0703,2592,7562,7502,953Current tax assets3192160191177158138138138208287000Account receivable4,1974,2073,3013,7263,4003,4553,3793,2813,6473,9903,8773,6253,5023,646Accrued income1,6991,8952,1261,6401,1601,4011,5261,7721,7962,1192,0502,2612,2612,261Derivative financial instruments000000010011316400Other current receivables6697787888941,3211,1761,3671,3641,6891,5971,5431,8201,8201,820Cash and cash equivalents2,2473,2652,2733,3824,4584,0736,4074,4113,0773,2782,7792,9552,6902,558Current assets9,92111,5349,78310,76913,07812,89715,56613,24712,88014,37513,95813,41713,02313,238Total Assets17,89221,18419,44220,95023,75924,06428,41124,84426,30329,60831,41328,97729,08929,826Total Equity and LiabilitiesParent company shareholders6,2496,6386,4026,7746,9877,7788,1138,1978,9139,72910,7748,8039,1119,614Minority interest881000110345454949Total shareholders&#x27; equity6,2576,6466,4126,7746,9877,7798,1148,1978,9169,73310,7798,8489,1609,663Deferred tax liabilities687732690778511587545502576473416000Other long-term provisions131279140142158188235235235237236000Long-term interest-bearing liabilities4,3614,9584,9375,2724,3693,5587,1013,0434,0995,7064,8076,1956,1956,195Other liabilities80733363557373734185626626626Lease liabilities0000001,0438548417121,095961961961Total long-term liabilities5,1875,9695,8406,2255,1014,3888,9974,7075,8247,1696,6397,7817,7817,781Short-term provisions16999347231186188179179179189148000Short-term interest-bearing liabilities1251,0751309751,0001,0012,141510141,122178178178Lease liabilities000000213200245236224233233233Current tax liabilities21911993111107166246246246202200000Accounts payable1,2951,2621,1221,0001,1321,4271,0251,0161,3521,8091,5501,8371,7751,848Advances for customer1,6862,1651,9432,5315,3164,8834,1033,7594,1615,0114,8934,0673,9294,091Derivative financial instruments000000010019610800Other current liabilities2,9543,8493,6724,0783,9554,2334,5354,3994,8715,0495,7526,0336,0336,033Current liabilities6,4488,5697,1907,95111,67111,89711,30011,94111,56412,70613,99512,34812,14812,382Total Equity and Liabilities17,89221,18419,44220,95023,75924,06428,41124,84426,30329,60831,41328,97729,08929,826Total debt (gross)4,4866,0334,9505,2725,3444,5589,3586,2385,6946,6687,2477,5677,5677,567Net debt / (cash) - incl. Lease liabilities2,2392,7682,6771,8908864852,9501,8282,6173,3904,4684,6124,8775,009Net Debt / EBITDA (incl. Lease liabilities)1.0x1.9x1.6x1.1x0.4x0.2x1.0x0.6x1.0x1.2x1.4x1.4x1.5x1.4x",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "9688fdab606b3479",
      "text": "Source:Jefferies estimates, company data",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "0cf448ba052a891a",
      "text": "Exhibit 10-EKTAB CF Statement",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "92a4a9beba1569ce",
      "text": "Cash Flow Statement (SEKm)2013/142014/152015/162016/172017/182018/192019/202020/212021/222022/232023/242024/252025/26e2026/27eProfit for the year / before tax1,5027161893401,6811,5801,4541,6301,5011,1981,6684901,5761,820Depreciation &amp;amp; Amortization4145126346556759431,2751,2041,0391,0621,1361,2991,2691,305Other non-cash items (including gross capital, R&amp;amp;D)(292)(77)(239)(305)(283)(341)(351)(165)(1,262)(1,039)(766)532(747)(794)Change in working capital(317)5244611,0514(636)(1,512)(109)(12)(150)(220)(203)(71)(113)Interest received22223731676663304279108283027Interest paid(189)(192)(233)(219)(165)(175)(208)(250)(156)(235)(365)(416)(400)(368)Income tax paid(353)(362)(269)(268)(250)(269)(261)(465)(452)(290)(431)(311)(347)(401)Taxes unpaid0000(3)100000000Cash flow from operating activities7871,1435801,2851,7681,1774601,8757006251,1281,4191,3101,477Capital expenditures (maintenance)(236)(276)(184)(240)(179)(206)(207)(169)(251)(226)(313)(363)(368)(401)Other investment / Acquisitions(52)(188)(12)(18)(141)(16)(537)232(241)(51)(278)(102)(50)(50)Cash flow from investing activities(288)(464)(196)(258)(320)(222)(744)63(492)(277)(591)(465)(418)(451)Borrowings12950(1,113)1,99615-3,543--1,556123550--Repayment of debt(97)--(1,829)-(938)-(2,694)(657)(500)(16)---New issues, warrant premiums and repurchase of shares-------Dividend(770)(763)(190)(201)(382)(535)(688)(688)(841)(917)(917)(917)(917)(117)Minority contribution(33)--(21)--(232)(223)(229)(268)(289)(241)(241)(241)Repayment of lease liabilities-------(232)(223)(229)(268)(289)(241)(241)Cash flow from financing activities(888)187(1,303)(55)(367)(1,473)2,623(3,605)(1,727)(129)(1,099)(608)(1,158)(1,158)Free Cash Flow5518673961,0451,5899722531,7064504008151,0569421,075Liquid funds at beginning of the year2,5662,2473,2662,2743,3834,4584,0736,4074,4103,0763,2782,7782,9552,690Translation differences on liquid funds70153(73)137(8)142(5)(329)183(18)62(170)00Cash flow from the year(389)866(919)9721,081(518)2,339(1,667)(1,518)220(562)347(265)(132)Liquid funds at year-end2,2473,2662,2743,3834,4584,0826,4074,4103,0763,2782,7782,9552,6902,558",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "34307ab66771f5c9",
      "text": "Source: Jefferies estimates, company data",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "13b25a59ed4c2940",
      "text": "Elekta develops tools and treatment planning systems for radiation therapy, radiosurgery, and brachytherapy, as well as software systems used in cancer care.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7e2ba80d832861be",
      "text": "Our PT is based on DCF. Risks include reversal of market share losses leading to sales growth above guidance and accelerated margin expansion. Unity mass adoption.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "ed5e99890ec9b95c",
      "text": "(Article 3(1)e and Article 7 of MAR) Recommendation Published Recommendation Distributed",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c364a91236e153f3",
      "text": "August 28, 2025 14:33 P.M. August 28, 2025 14:33 P.M.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "061b83628567a0c6",
      "text": "Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of \\(15\\%\\) or more within a 12- month period. Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus \\(15\\%\\) or minus \\(10\\%\\) within a 12- month period.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "361b4c932ac643c8",
      "text": "Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus \\(10\\%\\) or less within a 12- month period. The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \\(10 is 20\\%\\) or more within a 12- month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \\(10, the expected total return (price appreciation plus yield) is plus or minus 20\\% with a 12 - month period. For Underperform rated securities with an average security price consistently below\\) 10, the expected total return (price appreciation plus yield) is minus \\(20\\%\\) or less within a 12- month period.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e776b82d731fe4f0",
      "text": "NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "787e23fee166a4e4",
      "text": "CS - Coverage Suspended. Jefferies has suspended coverage of this company.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "0a8a1ff7d203e45b",
      "text": "NC - Not covered. Jefferies does not cover this company.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "baef0bb7c8286e57",
      "text": "Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "ee1cf8f78dd32e13",
      "text": "Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "907f18a0e0728935",
      "text": "Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "8e35cd0ccfc382fc",
      "text": "Jefferies Franchise PicksJefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "619820a2cb51bfd3",
      "text": "- Elekta (EKTAB SS: SEK48.94, HOLD)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "51c58b350523e0aa",
      "text": "Rating and Price Target History for: Elekta (EKTAB SS) as of 08-27-2025",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "a2f009e6f13c2466",
      "text": "Notes: Each box in the Rating and Price Target History chart above represents actions over the past three years in which an analyst initiated on a company, made a change to a rating or price target of a company or discontinued coverage of a company.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "29b31bea1245d75c",
      "text": "I: Initiating Coverage",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "07854270b82b27e9",
      "text": "Distribution of Ratings",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c6f7067426d8f912",
      "text": "CountPercentCountPercentCountPercentBUY211260.69%36717.38%1175.54%HOLD121134.80%1058.67%221.82%UNDERPERFORM1574.51%31.91%31.91%",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "c421f95e19e68d8b",
      "text": "Jefferies does busines and seeks to do busines with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "79d3e0a6a9219f39",
      "text": "Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Financial Group Inc. (Jefferies) companies: United States: Jefferies LLC which is an SEC registered broker- dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "d45b9d8210df78ab",
      "text": "Canada: Jefferies Securities Inc., which is an investment dealer registered in each of the thirteen Canadian jurisdictions and a dealer member of the Canadian Investment Regulatory Organization, including research reports produced jointly by Jefferies Securities Inc. and another Jefferies entity (and distributed by Jefferies Securities Inc.).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "54ee46a693245364",
      "text": "Where Jefferies Securities Inc. distributes research reports produced by Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch or Jefferies India Private Limited, you are advised that each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited operates as a dealer in your jurisdiction under an exemption from the dealer registration requirements contained in National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations and, as such, each of Jefferies LLC, Jefferies International Limited, Jefferies (Japan) Limited, Tokyo Branch and Jefferies India Private Limited is not required to be and is not a registered dealer or adviser in your jurisdiction. You are advised that where Jefferies LLC or Jefferies International Limited prepared this research report, it was not prepared in accordance with Canadian disclosure requirements relating to research reports in Canada.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "f74cfa6a157c5d9f",
      "text": "United Kingdom: Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority, registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "941616362cdc6040",
      "text": "Japan: Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1- 1- 2 Yurakucho, Chiyoda- ku, Tokyo 100- 0006; telephone +813 5251 6100; facsimile +813 5251 6101.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "59b6388ead0344cd",
      "text": "Australia: Jefferies (Australia) Pty Limited (ACN 623 059 898), which holds an Australian financial services license (AFSL 504712) and is located at Level 20, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "baae3183e618f3e0",
      "text": "Dubai: Jefferies International Limited, Dubai branch, which is licensed by the Dubai Financial Services Authority (DFSA Reference Number F007325); registered office Unit L31- 06, L31- 07, Level 31, ICD Brookfield Pace, DIFC, PO Box 121208, Dubai, UAE.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "d729fd6eaca28415",
      "text": "This report was prepared by personnel who are associated with Jefferies (Jefferies Securities Inc., Jefferies International Limited, Jefferies GmbH, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), and Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC (\"JRS\"). Jefferies LLC is a US registered broker- dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as \"Jefferies\". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA, the Canadian Investment Regulatory Organization and other rules are set forth in this disclosure section.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7a5fe8406428ad94",
      "text": "If you are receiving this report from a non- US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a- 6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited (\"JIL\") and/or Jefferies GmbH and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed. Jefferies LLC, JIL, Jefferies GmbH and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under \"company specific disclosures\".",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "4fc7d1035e688bfd",
      "text": "For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a permitted client as defined by National Instrument 31- 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations, as applicable. This research report is a general discussion of the merits and risks of a security or securities only, and is not in any way meant to be tailored to the needs and circumstances of any recipient. The information contained herein is not, and under no circumstances is to be construed as, an offer to sell securities described herein, or solicitation of an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators, if applicable, and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed judgment upon this research report, the information contained herein or the merits of the securities described herein, and any representation to the contrary is an offence.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "67ba9f89a804c477",
      "text": "By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker- dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser, and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "a571b703fd101e27",
      "text": "The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e681f7b581b60875",
      "text": "This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9d44f453d26baee8",
      "text": "This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "6689541c5fbdccd6",
      "text": "This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's, and information derived from third-party or proprietary generative artificial intelligence (Gen AI) models. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of this information, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Neither Jefferies nor any third-party content providers, including providers of Gen AI models, give any express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "afb15a5f8fc4190b",
      "text": "Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be copied, reprinted, sold, or redistributed or disclosed by the recipient or any third party, by content scraping or extraction, automated processing, or any other form or means, without the prior written consent of Jefferies. Any unauthorized use is prohibited. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "5c76ff603ee37473",
      "text": "For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd_iapd_Brochure.aspx? BRCHR_VRSN_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.",
      "page": 15,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "db4bfed361d0c241",
      "name": "Adj EBIT",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b86fc85fa56f47ac",
      "name": "Adj EPS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "76362b9a498a65d1",
      "name": "All Hopes",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e79b38eac28ec1ea",
      "name": "Ambitious MT",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b7c729c0e2366001",
      "name": "Balance Sheet",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "091ea27f0512d847",
      "name": "Base Case",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3783a8579f5b7aa1",
      "name": "CEO Jakob",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7860a2554c61a53f",
      "name": "Canadian Investment",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc62425edd02dcb2",
      "name": "Cash Flow",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f5b8c080cdc5f7aa",
      "name": "Catalysts\n\nTop",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f2c3fd855dab9335",
      "name": "Chat Series",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "0e79c84cd58b0944",
      "name": "China\n\nDespite",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6e4788dbad025b7b",
      "name": "Company Description",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8bb7d9a681cb9e40",
      "name": "Company Valuation",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4b9be408e155a05b",
      "name": "Coverage Suspended",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e9cd18ef1469e32c",
      "name": "DFSA Reference",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6ba4b0a762d135f4",
      "name": "Dealers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2b652ed713a34566",
      "name": "Devices\n\nElekta",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3a9f1e728b314846",
      "name": "Disclosures\n\nJefferies",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98c5e1b74a254ba0",
      "name": "Downside Scenario",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "f3375fbe9f083b6a",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "other",
        "title": "Elekta results vs consensus",
        "page": 3,
        "axes": null,
        "series": [],
        "figure_id": "384a60904b4d94db",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "combo",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1Q 17/18",
              "2Q 17/18",
              "3Q 17/18",
              "4Q 17/18",
              "1Q 18/19",
              "2Q 18/19",
              "3Q 18/19",
              "4Q 18/19",
              "1Q 19/20",
              "2Q 19/20",
              "3Q 19/20",
              "4Q 19/20",
              "1Q 20/21",
              "2Q 20/21",
              "3Q 20/21",
              "4Q 20/21",
              "1Q 21/22",
              "2Q 21/22",
              "3Q 21/22",
              "4Q 21/22",
              "1Q 22/23",
              "2Q 22/23",
              "3Q 22/23",
              "4Q 22/23",
              "1Q 23/24",
              "2Q 23/24",
              "3Q 23/24",
              "4Q 23/24",
              "1Q 24/25",
              "2Q 24/25",
              "3Q 24/25",
              "4Q 24/25",
              "1Q 25/26"
            ]
          },
          "y": {
            "unit": "SEK m",
            "range": {
              "min": 0,
              "max": 7000
            }
          }
        },
        "series": [
          {
            "name": "Order intake",
            "unit": "SEK m",
            "values": [
              2700,
              3200,
              1700,
              3800,
              3900,
              4700,
              3600,
              5300,
              4400,
              5500,
              4200,
              4000,
              4500,
              1500,
              3000,
              5400,
              3800,
              4100,
              4500,
              5900,
              4700,
              4800,
              5200,
              6400,
              4800,
              5000,
              6300,
              4200,
              4300,
              4500,
              5300,
              5700,
              3600
            ]
          },
          {
            "name": "% growth at cc (12m rolling)",
            "unit": "%",
            "values": [
              10,
              11,
              6,
              9,
              10,
              12,
              11,
              13,
              12,
              14,
              15,
              15,
              13,
              4,
              2,
              5,
              8,
              9,
              10,
              11,
              7,
              6,
              6,
              7,
              4,
              1,
              2,
              0,
              2,
              -1,
              1,
              0,
              -3
            ]
          }
        ],
        "figure_id": "f3bcc8378e1d7754",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1Q 14/15",
              "4Q 14/15",
              "3Q 15/16",
              "2Q 16/17",
              "1Q 17/18",
              "4Q 17/18",
              "3Q 18/19",
              "2Q 19/20",
              "1Q 20/21",
              "4Q 20/21",
              "3Q 21/22",
              "2Q 22/23",
              "1Q 23/24",
              "4Q 23/24",
              "3Q 24/2"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -15,
              "max": 20
            }
          }
        },
        "series": [
          {
            "name": "Order growth (12m roll)",
            "unit": "%",
            "values": [
              2.0,
              -10.0,
              -14.0,
              -2.0,
              13.0,
              -2.0,
              12.0,
              -6.0,
              -2.0,
              8.0,
              -2.0,
              2.0,
              -8.0,
              -5.0,
              -7.0
            ]
          },
          {
            "name": "Sales growth (12m roll)",
            "unit": "%",
            "values": [
              1.0,
              -6.0,
              -4.0,
              -11.0,
              8.0,
              9.0,
              11.0,
              -2.0,
              0.0,
              5.0,
              4.0,
              2.0,
              9.0,
              2.0,
              2.0
            ]
          },
          {
            "name": "MT sales target",
            "unit": "%",
            "values": [
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0,
              7.0
            ]
          }
        ],
        "figure_id": "13e98ad440ed00a7",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 7,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "07/24/2015",
              "01/22/2016",
              "07/22/2016",
              "01/20/2017",
              "07/21/2017",
              "01/19/2018",
              "07/20/2018",
              "01/19/2019",
              "07/19/2019",
              "01/17/2020",
              "07/17/2020",
              "01/15/2021",
              "07/16/2021",
              "01/14/2022",
              "07/15/2022",
              "01/13/2023",
              "07/14/2023",
              "01/12/2024",
              "07/12/2024",
              "01/10/2025",
              "07/11/2025"
            ]
          },
          "y": {
            "unit": "x",
            "range": {
              "min": 10,
              "max": 35
            }
          }
        },
        "series": [
          {
            "name": "Elekta",
            "unit": "x",
            "values": [
              18.5,
              19.5,
              14.5,
              16.5,
              25.5,
              20.5,
              29.0,
              28.0,
              24.0,
              28.5,
              23.0,
              28.5,
              27.0,
              28.5,
              17.0,
              13.0,
              18.0,
              17.0,
              13.0,
              12.0,
              11.0
            ]
          },
          {
            "name": "Medical Equipment Peers",
            "unit": "x",
            "values": [
              15.0,
              17.0,
              14.0,
              13.0,
              18.0,
              19.0,
              20.0,
              24.0,
              19.0,
              15.0,
              21.0,
              23.0,
              25.0,
              24.0,
              19.0,
              18.0,
              21.0,
              19.0,
              18.0,
              16.0,
              17.0
            ]
          }
        ],
        "figure_id": "5e6a570834377230",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 7,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "07/24/2015",
              "01/22/2016",
              "07/22/2016",
              "01/20/2017",
              "07/21/2017",
              "01/19/2018",
              "07/20/2018",
              "01/18/2019",
              "07/19/2019",
              "01/17/2020",
              "07/17/2020",
              "01/15/2021",
              "07/16/2021",
              "01/14/2022",
              "07/15/2022",
              "01/13/2023",
              "07/14/2023",
              "01/12/2024",
              "07/12/2024",
              "01/10/2025",
              "07/11/2025"
            ]
          },
          "y": {
            "left": {
              "unit": "x",
              "label": "12m fwd P / E",
              "range": {
                "min": 10,
                "max": 40
              }
            },
            "right": {
              "unit": "%",
              "label": "Relative value vs peers",
              "range": {
                "min": 0,
                "max": 150
              }
            }
          }
        },
        "series": [
          {
            "name": "Elekta",
            "unit": "x",
            "values": [
              17.5,
              20,
              22,
              20,
              24,
              22,
              28,
              24,
              26,
              20,
              15,
              25,
              28,
              26,
              18,
              14,
              18,
              16,
              14,
              12,
              11
            ]
          },
          {
            "name": "EU MedTech",
            "unit": "x",
            "values": [
              21,
              22,
              21,
              22,
              23,
              24,
              26,
              22,
              24,
              26,
              28,
              30,
              32,
              26,
              22,
              24,
              20,
              22,
              24,
              22,
              20
            ]
          },
          {
            "name": "Relative value vs peers (shaded area)",
            "unit": "%",
            "values": [
              70,
              80,
              90,
              85,
              95,
              100,
              110,
              95,
              105,
              100,
              115,
              125,
              130,
              110,
              90,
              95,
              80,
              90,
              95,
              90,
              85
            ]
          }
        ],
        "figure_id": "33b3b7c1a51b6883",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "line",
        "title": "Rating and Price Target History for: Elekta (EKTAB SS) as of 08-27-2025",
        "page": 13,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "SEK",
            "range": {
              "min": 40,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Price",
            "unit": "SEK",
            "values": [
              {
                "date": "2022-10-17",
                "value": 55.0
              },
              {
                "date": "2023-02-06",
                "value": 64.0
              },
              {
                "date": "2023-03-30",
                "value": 62.0
              },
              {
                "date": "2023-11-30",
                "value": 85.0
              },
              {
                "date": "2024-09-04",
                "value": 76.0
              },
              {
                "date": "2024-11-29",
                "value": 73.0
              },
              {
                "date": "2025-02-25",
                "value": 66.0
              },
              {
                "date": "2025-06-02",
                "value": 53.0
              }
            ]
          }
        ],
        "figure_id": "32095a8a10473ea3",
        "provenance": {
          "page": 13
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "d20fce6e60c192c7",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "etter H2H2H2H2H2H2H2H2H2H2H2 Slow start to the year as guided with Q1 results broadly in line: OSG 2.5% (cons \\(+1.9\\%),\\) adj mgin 6.5% (cons 6.1%) and order book down 1%cc (cons-2%).Vague FY25/26 gu",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "54a36aa437789c98",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "w start to the year as guided with Q1 results broadly in line: OSG 2.5% (cons \\(+1.9\\%),\\) adj mgin 6.5% (cons 6.1%) and order book down 1%cc (cons-2%).Vague FY25/26 guide (sales growth; no mgin targe",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "707829910dfbc84a",
        "value": 0.061,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "the year as guided with Q1 results broadly in line: OSG 2.5% (cons \\(+1.9\\%),\\) adj mgin 6.5% (cons 6.1%) and order book down 1%cc (cons-2%).Vague FY25/26 guide (sales growth; no mgin target) reiterat",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1c5c567e049039b8",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "results broadly in line: OSG 2.5% (cons \\(+1.9\\%),\\) adj mgin 6.5% (cons 6.1%) and order book down 1%cc (cons-2%).Vague FY25/26 guide (sales growth; no mgin target) reiterated, as is MT guide for mgin",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "677e75c198b5d35c",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "roadly in line: OSG 2.5% (cons \\(+1.9\\%),\\) adj mgin 6.5% (cons 6.1%) and order book down 1%cc (cons-2%).Vague FY25/26 guide (sales growth; no mgin target) reiterated, as is MT guide for mgin returnin",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b9d0d96a176938a9",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Vague FY25/26 guide (sales growth; no mgin target) reiterated, as is MT guide for mgin returning to 14% and higher. Shares down \\(\\sim 25\\%\\) YTD, reflecting external pressures (tariffs, hospital budg",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4d58403bd86c7e66",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s still in negative territory.** Facing tough comps \\((+10\\%\\) in 1Q24/25), the order book declined 1%cc (cons -2%cc). This is in spite of the recent launch of new Iinac Evo and new additions to the s",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8373609c820494d5",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "negative territory.** Facing tough comps \\((+10\\%\\) in 1Q24/25), the order book declined 1%cc (cons -2%cc). This is in spite of the recent launch of new Iinac Evo and new additions to the software sui",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0a387b9816e0f4f6",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f uninspiring order intake (avg down \\(>1\\%\\) over the past 2Y). **Sales in line.** Q1 OSG reached 2.5% (cons \\(+1.9\\%),\\) mainly driven by strong performance in Europe while China and US sales contin",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5830eed1118859ab",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "GM pullback (down 80bp y/y), burdened by FX (100bp) and tariffs (90bp). Adj. EBIT margin landed at 6.5% (cons 6.1%), down 90bp y/y. We stress Q1 usually accounts for \\(\\sim 10\\%\\) of FY EBIT due to se",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9dbef54c4df8f959",
        "value": 0.061,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "k (down 80bp y/y), burdened by FX (100bp) and tariffs (90bp). Adj. EBIT margin landed at 6.5% (cons 6.1%), down 90bp y/y. We stress Q1 usually accounts for \\(\\sim 10\\%\\) of FY EBIT due to seasonality.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9524554a19aa0973",
        "value": 0.11699999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ated.** EKTAB expects sales to grow in FY25/26 (cons. \\(+4.6\\%cc)\\) but still no mgin target (cons. 11.7% vs 11.6% in FY24/25). Q2 sales are expected to be negatively impacted by continued US weakness",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5c64c398f17543ee",
        "value": 0.11599999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "KTAB expects sales to grow in FY25/26 (cons. \\(+4.6\\%cc)\\) but still no mgin target (cons. 11.7% vs 11.6% in FY24/25). Q2 sales are expected to be negatively impacted by continued US weakness and unin",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cb704fdb0efae762",
        "value": 0.129,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "standing MT targets to move GM back to pre-COVID levels ( \\(>40\\%\\) ) and EBIT mgin \\(>14\\%\\) (cons 12.9% in FY28/29). More precise financial targets/pathway will likely be at the initiative of the in",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "90a9ddae4712f4de",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">HOLD</td></tr><tr><td>PRICE</td><td>SEK48.94*</td></tr><tr><td>PRICE TARGET|% TOP</td><td>SEK53.00|+8%</td></tr><tr><td>52W HIGH-LOW</td><td>SEK76.30-SE K40.64</td></tr><tr><td>FLOAT (%)|ADV MM (USD)",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0e62d35c40e95e23",
        "value": 0.945,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>52W HIGH-LOW</td><td>SEK76.30-SE K40.64</td></tr><tr><td>FLOAT (%)|ADV MM (USD)</td><td>94.5%|3.63</td></tr><tr><td>MARKET CAP</td><td>SEK18.78|$2.0B</td></tr><tr><td>TICKER</td><td>EKTAB ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2843647e9d236595",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>CHANGE TO JEFe</td><td>JEF vs CONS</td></tr></table> <table><tr><td>REV*</td><td>NM</td><td>&lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%<",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b967c60adff2f41b",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "O JEFe</td><td>JEF vs CONS</td></tr></table> <table><tr><td>REV*</td><td>NM</td><td>&lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%</td></tr></",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9a750d2bf8023995",
        "value": -0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>JEF vs CONS</td></tr></table> <table><tr><td>REV*</td><td>NM</td><td>&lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%</td></tr></table> <tabl",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5a19c3b66551ff53",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<table><tr><td>REV*</td><td>NM</td><td>&lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%</td></tr></table> <table><tr><td>2026 (SEK)</td><td>Q1</",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4fd5006c98b6f7a2",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "EV*</td><td>NM</td><td>&lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%</td></tr></table> <table><tr><td>2026 (SEK)</td><td>Q1</td><td>Q2</td><t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5b6985ad09f79fba",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "NM</td><td>&lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%</td></tr></table> <table><tr><td>2026 (SEK)</td><td>Q1</td><td>Q2</td><td>Q3</td><td",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7db4c8945600de1c",
        "value": -0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "lt;1%</td><td>-2%</td><td>-3%</td></tr><tr><td>EPS*</td><td>+1%</td><td>&lt;-1%</td><td>-7%</td><td>-7%</td></tr></table> <table><tr><td>2026 (SEK)</td><td>Q1</td><td>Q2</td><td>Q3</td><td>Q4</td><td>",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4d58403bd86c7e66",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "s still in negative territory.** Facing tough comps \\((+10\\%\\) in 1Q24/25), the order book declined 1%cc (cons -2%cc). This is in spite of the recent launch of new Iinac Evo and new additions to the s",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8373609c820494d5",
        "value": -0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "negative territory.** Facing tough comps \\((+10\\%\\) in 1Q24/25), the order book declined 1%cc (cons -2%cc). This is in spite of the recent launch of new Iinac Evo and new additions to the software sui",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0a387b9816e0f4f6",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f uninspiring order intake (avg down \\(>1\\%\\) over the past 2Y). **Sales in line.** Q1 OSG reached 2.5% (cons \\(+1.9\\%),\\) mainly driven by strong performance in Europe while China and US sales contin",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5830eed1118859ab",
        "value": 0.065,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "GM pullback (down 80bp y/y), burdened by FX (100bp) and tariffs (90bp). Adj. EBIT margin landed at 6.5% (cons 6.1%), down 90bp y/y. We stress Q1 usually accounts for \\(\\sim 10\\%\\) of FY EBIT due to se",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9dbef54c4df8f959",
        "value": 0.061,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "k (down 80bp y/y), burdened by FX (100bp) and tariffs (90bp). Adj. EBIT margin landed at 6.5% (cons 6.1%), down 90bp y/y. We stress Q1 usually accounts for \\(\\sim 10\\%\\) of FY EBIT due to seasonality.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9524554a19aa0973",
        "value": 0.11699999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ated.** EKTAB expects sales to grow in FY25/26 (cons. \\(+4.6\\%cc)\\) but still no mgin target (cons. 11.7% vs 11.6% in FY24/25). Q2 sales are expected to be negatively impacted by continued US weakness",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5c64c398f17543ee",
        "value": 0.11599999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "KTAB expects sales to grow in FY25/26 (cons. \\(+4.6\\%cc)\\) but still no mgin target (cons. 11.7% vs 11.6% in FY24/25). Q2 sales are expected to be negatively impacted by continued US weakness and unin",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "cb704fdb0efae762",
        "value": 0.129,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "standing MT targets to move GM back to pre-COVID levels ( \\(>40\\%\\) ) and EBIT mgin \\(>14\\%\\) (cons 12.9% in FY28/29). More precise financial targets/pathway will likely be at the initiative of the in",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8b58f91f26b544dc",
        "value": 2000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</tr><tr><td>FLOAT (%)|ADV MM (USD)</td><td>94.5%|3.63</td></tr><tr><td>MARKET CAP</td><td>SEK18.78|$2.0B</td></tr><tr><td>TICKER</td><td>EKTAB SS</td></tr></table> *Prior trading day's closing price ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "04550c448ef77ba5",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>JFEe vs<br>cons.</td></tr><tr><td>Total Orders</td><td>4,192</td><td>3,838</td><td>3,822</td><td>0%</td><td>19,719</td><td></td><td>19,321</td><td>19,339</td><td>0%</td></tr><tr><td>% reported grow",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f80803ca0d1883e3",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>3,838</td><td>3,822</td><td>0%</td><td>19,719</td><td></td><td>19,321</td><td>19,339</td><td>0%</td></tr><tr><td>% reported growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "785fe05c235ddefd",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "19,719</td><td></td><td>19,321</td><td>19,339</td><td>0%</td></tr><tr><td>% reported growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b1ad02e9a09bc302",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td>19,321</td><td>19,339</td><td>0%</td></tr><tr><td>% reported growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e00fcaa82e8c67bd",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9,321</td><td>19,339</td><td>0%</td></tr><tr><td>% reported growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cce4b4dd87f6f728",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td></tr><tr><td>% reported growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "790312b018afcba6",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>% reported growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "c270d3e70fac7e2f",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rted growth</td><td>9%</td><td>(8%)</td><td>(9%)</td><td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f42ea36353c21913",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></td><td>0%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td>2%</td><td></td><td>4%</td><td>4%</td><td></td></tr><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "374844302dd4d1d6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td></td><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td>2%</td><td></td><td>4%</td><td>4%</td><td></td></tr><tr><td>Sales ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5e0993ea1727fd7a",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>(2%)</td><td>(2%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td>2%</td><td></td><td>4%</td><td>4%</td><td></td></tr><tr><td>Sales - Americas</t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2f9c3a32c111e33e",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%)</td><td></td></tr><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td>2%</td><td></td><td>4%</td><td>4%</td><td></td></tr><tr><td>Sales - Americas</td><td>1,241</td><td>1",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "ebb43b5d5a12089e",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><tr><td>% growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td>2%</td><td></td><td>4%</td><td>4%</td><td></td></tr><tr><td>Sales - Americas</td><td>1,241</td><td>1,071</td><td>1,023</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5b24decf494c565b",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "growth at CER</td><td>10%</td><td>(1%)</td><td>(2%)</td><td></td><td>2%</td><td></td><td>4%</td><td>4%</td><td></td></tr><tr><td>Sales - Americas</td><td>1,241</td><td>1,071</td><td>1,023</td><td>5%</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "86d703a8f43d8784",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>4%</td><td></td></tr><tr><td>Sales - Americas</td><td>1,241</td><td>1,071</td><td>1,023</td><td>5%</td><td>5,183</td><td></td><td>4,802</td><td>4,808</td><td>0%</td></tr><tr><td>% organic</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "72a1f361c9a78066",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1</td><td>1,071</td><td>1,023</td><td>5%</td><td>5,183</td><td></td><td>4,802</td><td>4,808</td><td>0%</td></tr><tr><td>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d73780bd8bceb3eb",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5%</td><td>5,183</td><td></td><td>4,802</td><td>4,808</td><td>0%</td></tr><tr><td>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></td><td>3%</td><td>2%</td><td></td></tr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "f8ac667908e9abd2",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "183</td><td></td><td>4,802</td><td>4,808</td><td>0%</td></tr><tr><td>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></td><td>3%</td><td>2%</td><td></td></tr><tr><td>Sale",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7751a674c1192d1c",
        "value": 0.07,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>4,802</td><td>4,808</td><td>0%</td></tr><tr><td>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></td><td>3%</td><td>2%</td><td></td></tr><tr><td>Sales - EMEA</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "cfac609fe0c38f75",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4,808</td><td>0%</td></tr><tr><td>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></td><td>3%</td><td>2%</td><td></td></tr><tr><td>Sales - EMEA</td><td>1,314</td><td>1,44",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "df5f4671f9dc4082",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></td><td>3%</td><td>2%</td><td></td></tr><tr><td>Sales - EMEA</td><td>1,314</td><td>1,443</td><td>1,381</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0a0d7e6cc04ad6d3",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>% organic</td><td>16%</td><td>(4%)</td><td>(7%)</td><td></td><td>(2%)</td><td></td><td>3%</td><td>2%</td><td></td></tr><tr><td>Sales - EMEA</td><td>1,314</td><td>1,443</td><td>1,381</td><td>4%</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "eeeabfaed5b62f1c",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>2%</td><td></td></tr><tr><td>Sales - EMEA</td><td>1,314</td><td>1,443</td><td>1,381</td><td>4%</td><td>6,580</td><td></td><td>6,694</td><td>6,705</td><td>0%</td></tr><tr><td>% organic</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8e71ab2800657807",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>1,443</td><td>1,381</td><td>4%</td><td>6,580</td><td></td><td>6,694</td><td>6,705</td><td>0%</td></tr><tr><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "532e7062d2cd87d1",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>6,580</td><td></td><td>6,694</td><td>6,705</td><td>0%</td></tr><tr><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td><td>5%</td><td>4%</td><td></td></tr><tr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4479e65b36945c7c",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "80</td><td></td><td>6,694</td><td>6,705</td><td>0%</td></tr><tr><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td><td>5%</td><td>4%</td><td></td></tr><tr><td>Sales - ",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "5fe324e5ed31a3eb",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>6,694</td><td>6,705</td><td>0%</td></tr><tr><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td><td>5%</td><td>4%</td><td></td></tr><tr><td>Sales - APAC</td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "26b347fa2fc7670c",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>6,705</td><td>0%</td></tr><tr><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td><td>5%</td><td>4%</td><td></td></tr><tr><td>Sales - APAC</td><td>1,270</td><td>1,132",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "44446bbf04c07881",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td><td>5%</td><td>4%</td><td></td></tr><tr><td>Sales - APAC</td><td>1,270</td><td>1,132</td><td>1,232</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "19b82aaf9b3c02a3",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>% organic</td><td>(12%)</td><td>15%</td><td>8%</td><td></td><td>1%</td><td></td><td>5%</td><td>4%</td><td></td></tr><tr><td>Sales - APAC</td><td>1,270</td><td>1,132</td><td>1,232</td><td>(8%)</td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "6daf60caa99e0d05",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>4%</td><td></td></tr><tr><td>Sales - APAC</td><td>1,270</td><td>1,132</td><td>1,232</td><td>(8%)</td><td>6,254</td><td></td><td>6,128</td><td>5,893</td><td>(4%)</td></tr><tr><td>% organic</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "7adb8d7791a57e2e",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>1,132</td><td>1,232</td><td>(8%)</td><td>6,254</td><td></td><td>6,128</td><td>5,893</td><td>(4%)</td></tr><tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "465e8d58fa3cdaa0",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>6,254</td><td></td><td>6,128</td><td>5,893</td><td>(4%)</td></tr><tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><td>6%</td><td>1%</td><td></td></tr><tr>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "300d13cb222b09e7",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "54</td><td></td><td>6,128</td><td>5,893</td><td>(4%)</td></tr><tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><td>6%</td><td>1%</td><td></td></tr><tr><td>Group sa",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d091e90f59868ce2",
        "value": 0.05,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>6,128</td><td>5,893</td><td>(4%)</td></tr><tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><td>6%</td><td>1%</td><td></td></tr><tr><td>Group sales</td><td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "614a17abaf724352",
        "value": 0.04,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>5,893</td><td>(4%)</td></tr><tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><td>6%</td><td>1%</td><td></td></tr><tr><td>Group sales</td><td>3,825</td><td>3,646<",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "da4c39cd1ed6af43",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><td>6%</td><td>1%</td><td></td></tr><tr><td>Group sales</td><td>3,825</td><td>3,646</td><td>3,636</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "de2ca32211634d81",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tr><td>% organic</td><td>3%</td><td>(4%)</td><td>5%</td><td></td><td>4%</td><td></td><td>6%</td><td>1%</td><td></td></tr><tr><td>Group sales</td><td>3,825</td><td>3,646</td><td>3,636</td><td>0%</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "fe6f0c73ecd1960f",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>1%</td><td></td></tr><tr><td>Group sales</td><td>3,825</td><td>3,646</td><td>3,636</td><td>0%</td><td>18,016</td><td></td><td>17,623</td><td>17,405</td><td>(1%)</td></tr><tr><td>% reported gr",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "16c9f6483f7055fd",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>3,646</td><td>3,636</td><td>0%</td><td>18,016</td><td></td><td>17,623</td><td>17,405</td><td>(1%)</td></tr><tr><td>% reported growth</td><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "81551a6ecbf35913",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "016</td><td></td><td>17,623</td><td>17,405</td><td>(1%)</td></tr><tr><td>% reported growth</td><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "d90565f4a459e418",
        "value": 0.047,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>17,623</td><td>17,405</td><td>(1%)</td></tr><tr><td>% reported growth</td><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "02ccbbf9a9bbe182",
        "value": 0.049,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>17,405</td><td>(1%)</td></tr><tr><td>% reported growth</td><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% org",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9b007c762a20d034",
        "value": 0.006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td></tr><tr><td>% reported growth</td><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><t",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4507d9c84273ded5",
        "value": 0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "orted growth</td><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><td>2.5%</td><td>1.9%</td>",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "90ea4c835c83c3ca",
        "value": 0.034,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>(0.1%)</td><td>(4.7%)</td><td>(4.9%)</td><td></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><td>2.5%</td><td>1.9%</td><td></td><td>1.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "31a4914bf91ead75",
        "value": 0.008,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td>(0.6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><td>2.5%</td><td>1.9%</td><td></td><td>1.0%</td><td>sales growth</td><td>sales growth</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "510cde2cb3edbb54",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6%)</td><td></td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><td>2.5%</td><td>1.9%</td><td></td><td>1.0%</td><td>sales growth</td><td>sales growth</td><td>4.6%</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "427644451aa7d6c8",
        "value": 0.019,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>(2.2%)</td><td>(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><td>2.5%</td><td>1.9%</td><td></td><td>1.0%</td><td>sales growth</td><td>sales growth</td><td>4.6%</td><td>2.5%</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "9dd4ca05a06053e7",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">(3.4%)</td><td></td></tr><tr><td>% organic</td><td>0.8%</td><td>2.5%</td><td>1.9%</td><td></td><td>1.0%</td><td>sales growth</td><td>sales growth</td><td>4.6%</td><td>2.5%</td></tr><tr><td>% FX</td><",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "e52217cf6c8ea6f8",
        "value": 0.052000000000000005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "unches; capitalization rate should continue to come down, leading to net capitalized R&D shrinking (5.2% of sales in FY22/23 to 3.0% in FY24/25 - JEF expect <2.5% in FY25/26e). Overall moving to a pha",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "c1db364284598ba5",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "should continue to come down, leading to net capitalized R&D shrinking (5.2% of sales in FY22/23 to 3.0% in FY24/25 - JEF expect <2.5% in FY25/26e). Overall moving to a phase with ratio between capita",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "bfa2cf84df46bff3",
        "value": 0.025,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "leading to net capitalized R&D shrinking (5.2% of sales in FY22/23 to 3.0% in FY24/25 - JEF expect <2.5% in FY25/26e). Overall moving to a phase with ratio between capitalized and expensed R&D changin",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "4f668ffaee5ddca9",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ter cash conversion. No specific guide for R&D expensed through the P&L, but a stabilization at 9- 10% of sales seems fair.<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "ab8a6f0c9b7b77a2",
        "value": 0.15,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "f7380d708e72cc78",
        "value": 0.2,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not ",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "e8457249ff3fd866",
        "value": 0.6069,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>Count</td><td>Percent</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "1aa6f1224d71ae06",
        "value": 0.17379999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>Count</td><td>Percent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "cdaae463101ff514",
        "value": 0.0554,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ent</td></tr><tr><td>BUY</td><td>2112</td><td>60.69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "b429e74511b2fe96",
        "value": 0.348,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "69%</td><td>367</td><td>17.38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157<",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "08cb08b3654fc738",
        "value": 0.0867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "38%</td><td>117</td><td>5.54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "92c1a7d45055121c",
        "value": 0.0182,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".54%</td></tr><tr><td>HOLD</td><td>1211</td><td>34.80%</td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "ef8aff5b17fb78b0",
        "value": 0.0451,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>105</td><td>8.67%</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "8e5bcc7f13da9ec9",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>22</td><td>1.82%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "571282d4c160672c",
        "value": 0.0191,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td></tr><tr><td>UNDERPERFORM</td><td>157</td><td>4.51%</td><td>3</td><td>1.91%</td><td>3</td><td>1.91%</td></tr></table><｜end▁of▁sentence｜>",
        "provenance": {
          "page": 12
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 7,
      "tables_count": 0,
      "numerical_data_count": 97,
      "passages_count": 114,
      "entities_count": 20
    }
  }
}